Stocktoria
Scinai Immunotherapeutics Ltd. SCNI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2007-06-07
Scinai Immunotherapeutics Ltd. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | -202.3% | -88.1% | — | — | — |
| Operating margin | -575.3% | -1312.8% | — | — | — |
| Net margin | -633.6% | 728.9% | — | — | — |
| FCF margin | -461.9% | -964.6% | — | — | — |
| Return on assets | -71.5% | 35.7% | -37.2% | -21.4% | -25.6% |
| Return on equity | -102.5% | 48.1% | 142.3% | 329.3% | -835.6% |
| Current ratio | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 |
| Revenue growth | 99.2% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001611747 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.